Home About Login Current Archives Announcements Editorial Board
Submit Now For Authors Call for Submissions Statistics Contact
Home > Archives > Volume 20, No 8 (2022) > Article

DOI: 10.14704/nq.2022.20.8.NQ22978

Comparison of safety & efficacy of Metformin plus Glimepiride vs Metformin plus Sitagliptin in patients of Type 2 Diabetes mellitus with poor glycemic control, a randomized open label study

Dr. V. Srinivasan, Dr. J. Thirunavukkarasu

Abstract

Many studies have been reported in literature regarding initial combination of sitagliptin and metformin provided substantial and additive glycemic improvement and was generally well tolerated in patients with type 2 diabetes. There is not much comparative drug study comparing fixed dose combination of Metformin plus Glimepiride Vs Metformin plus Sitagliptin in patients of type 2 diabetes mellitus with poor glycemic control. This study was a randomized, double arm, open labeled, parallel group, prospective, active comparator clinical study comparing the safety & efficacy of Metformin plus Glimepiride and Metformin plus Sitagliptin in patients of type 2 diabetes mellitus with poor glycemic control. The study duration was 12 weeks (3 months), each randomized patient in two groups were assigned study drugs and were assessed periodically. So the rationale behind our study is to find which combination drug therapy has better efficacy, lesser side effects and more beneficial in long term therapy.

Keywords

Type 2 Diabetes Mellitus, Gliptins, Fixed Dose Combinations

Full Text

PDF

References

?>